interest
use
chloroquinehydroxychloroquin
cqhcq
azithromycin
azt
therapi
employ
cystic
fibrosi
respiratori
epitheli
cell
show
drug
azt
ciprofloxacin
cpx
act
acidotrop
lipophil
weak
base
confer
vitro
effect
intracellular
organel
similar
effect
cq
seemingli
dispar
fdaapprov
antimicrobi
display
common
properti
modul
ph
endosom
transgolgi
network
believ
may
part
help
understand
potenti
benefici
effect
cqhcq
azt
present
consider
hcq
azt
clinic
trial
extend
cpx
coronavirus
cov
famili
virus
caus
diseas
human
anim
includ
endem
human
cov
caus
mild
respiratori
tract
infect
common
cold
categori
ongo
rage
pandem
seriou
respiratori
diseas
caus
novel
coronaviru
foreshadow
two
notabl
prior
epidem
exhibit
high
mortal
high
preval
acut
respiratori
distress
syndrom
ard
arrhythmia
death
resolv
case
longterm
reduct
lung
function
disabl
current
approv
therapeut
vaccin
coronaviru
diseas
novel
sarscovlik
viru
relat
sarscov
distinct
form
identifi
caus
agent
current
outbreak
viral
pneumonia
start
wuhan
china
spread
perman
inhabit
contin
humantohuman
spread
result
runaway
global
pandem
caus
diseas
term
coronaviru
world
health
organ
pandem
escal
alarm
rate
infect
write
death
itali
spain
combin
mortal
rate
disproportion
affect
countri
away
epicent
initi
epidem
threaten
worldwid
popul
base
pernici
combin
long
incub
time
coupl
except
spread
potenti
significantli
high
morbid
mortal
reproduct
number
initi
estim
accord
estim
may
possibl
reach
urgent
public
health
need
understand
viru
diseas
frighten
epidemiolog
phenomenon
world
liter
scrambl
develop
countermeasur
includ
therapeut
aim
lessen
diseas
sever
come
prophylax
includ
vaccin
recent
two
fda
approv
drug
chloroquin
cq
azithromycin
azt
shown
therapeut
effect
use
viral
load
endpoint
compassion
useiniti
clinic
trial
associ
lifethreaten
pulmonari
complic
work
began
time
major
progress
made
understand
key
properti
anomal
ion
conduct
across
cystic
fibrosi
cf
respiratori
epithelia
defect
chlorid
transport
via
cystic
fibrosi
transmembran
conduct
regul
cftr
sodium
transport
via
epitheli
sodium
channel
enac
certain
drug
proven
use
treat
pulmonari
diseas
cf
azt
antibiot
stapl
clinic
manag
cf
cf
patient
treat
azt
benefit
sever
aspect
lung
function
decreas
rate
exacerb
experi
improv
qualiti
life
albeit
magnitud
benefit
may
vari
antibiot
mechan
azt
cf
might
expect
kill
bacteria
yet
tissu
level
macrolid
reach
necessari
antipseudomon
concentr
lung
provid
easi
explan
benefit
wherea
sever
studi
propos
effect
azt
bacteri
biofilm
compel
evid
hostmedi
effect
macrolid
import
sinc
azt
benefici
effect
cf
even
pseudomona
aeruginosa
colon
occur
ii
azt
protect
bronchial
epithelium
p
aeruginosa
infect
independ
antimicrobi
activ
thu
azt
confer
previous
undefin
antibioticindepend
benefit
document
cf
clinic
trial
routin
observ
cf
manag
howev
subsequ
studi
provid
cautionari
note
prolong
azt
use
cf
sinc
like
chloroquin
inhibit
autophagi
involv
control
mycobacteria
report
azt
ciprofloxacin
cpx
previous
demonstr
chloroquin
alter
ph
within
intracellular
organel
respiratori
epitheli
cell
correct
result
normal
cellautonom
immun
function
respiratori
epithelia
cf
effect
achiev
divers
set
fda
approv
drug
data
indic
azt
action
least
part
overlap
cq
mode
action
furthermor
propos
clinic
trial
patient
risk
develop
sever
drug
deacidifi
action
chloroquin
plan
warrant
consider
cpx
azithromycin
correct
organellar
ph
cf
lung
epitheli
cell
test
effect
azt
cf
respiratori
epitheli
cell
absenc
bacteria
microbi
innat
immun
agonist
among
test
employ
examin
ph
intracellular
organel
sinc
prior
studi
indic
organel
display
subtli
increas
acidif
cf
respiratori
epitheli
cell
relev
unlik
macrolid
show
littl
benefit
cf
azt
possess
two
weak
base
function
group
pka
fig
ph
lumen
transgolgi
network
tgn
recycl
endosom
cf
lung
cell
measur
ratiometr
appli
intracellular
phsensit
probe
phlourin
gfp
ph
sensit
gfp
fuse
cellubrevin
thu
local
phluorin
gfp
lumen
tgn
cf
respiratori
epitheli
cell
primari
cf
bronchial
epitheli
cell
treat
azt
display
correct
previous
report
tgn
hyperacidifc
fig
bg
treatment
cf
cell
either
h
azt
h
led
correct
tgn
ph
control
fig
compar
ph
within
tgn
cell
cftrcorrect
cell
primari
cf
bronchial
epitheli
cell
fig
azt
treatment
correct
tgn
ph
fig
note
absolut
concentr
azt
critic
effect
equilibrium
expect
extracellular
sink
acidotrop
agent
accumul
acidifi
compart
proton
trap
within
organellar
lumen
ph
recycl
endosom
cf
similarli
correct
azt
fig
g
treatment
cf
cell
azt
h
h
led
correct
ph
fig
primari
cf
bronchial
cell
azt
correct
ph
ph
fig
g
acidotrop
correct
acidifi
intracellular
compart
cf
respiratori
epitheli
cell
restrict
azithromycin
cpx
anoth
antibiot
fluoroquinolon
fig
effect
cf
also
weak
base
pka
test
cpx
effect
cf
cell
use
pcepr
cell
human
normal
bronchial
epitheli
cell
transfect
rregion
cftr
render
phenotyp
express
cf
characterist
found
cpx
h
correct
ph
tgn
fig
show
ph
correct
cf
limit
azt
antibiot
weak
base
chemic
properti
may
display
properti
clinic
studi
shown
adher
p
aeruginosa
epithelia
cf
patient
undergo
azt
therapi
reduc
base
find
azt
correct
acidif
tgn
cf
cell
investig
whether
azt
affect
undersialyl
reduc
bacteri
adher
cf
lung
epitheli
cell
propos
undersialyl
reduc
bind
cholera
toxin
one
evolutionari
driver
emerg
cftr
mutat
human
popul
explain
least
part
hyperacidif
tgn
result
suboptim
distribut
activ
sialyltransferas
glycosyl
enzym
organel
cf
normal
cell
grown
day
postconflu
follow
h
treatment
monolay
azt
monolay
assay
bind
cholera
toxin
subunit
b
ctb
conjug
fluorophor
fitc
ctb
bind
preferenti
sialyl
glycoconjug
fig
use
bind
ctb
cell
cftrcorrect
cell
bind
cell
cf
treatment
monolay
azt
increas
ctbfitc
bind
level
approach
noncf
cell
fig
ph
correct
effect
azt
correct
ctb
bind
concentr
independ
expect
accumul
acidotrop
agent
intraorganellar
trap
proton
next
test
azt
effect
p
aeruginosa
adhes
cf
cell
use
azt
lower
concentr
mic
p
aeruginosa
addit
monolay
wash
elimin
extracellular
azt
bacteri
adhes
assay
pretreat
cf
cell
azt
led
decreas
p
aeruginosa
bind
fig
result
confirm
use
pcepr
cell
human
normal
bronchial
epitheli
cell
transfect
rregion
cftr
pretreat
pcepr
cf
cell
azt
led
decreas
p
aeruginosa
bind
n
p
fig
confirm
find
cf
cell
azt
correct
immun
respons
cf
cell
challeng
bacteri
product
test
effect
azt
wellaccept
proinflammatori
phenotyp
cf
respiratori
epitheli
cell
measur
rant
respons
cell
treat
azt
basal
activ
reduc
compar
untreat
cell
cfcell
stimul
p
aeruginosa
lipopeptid
lpta
h
presenc
azt
macrolid
attenu
increas
stimul
respons
lpta
fig
find
keep
report
azt
weak
base
chloroquin
inhibitor
bafilomycin
vacuolar
h
atpas
amelior
proinflammatori
signal
cf
cell
level
increas
cf
increas
correct
treatment
weak
base
chloroquin
test
effect
azt
releas
basal
condit
upon
stimul
p
aeruginosa
dna
treatment
cfcell
azt
reduc
basal
secret
almost
fig
stimul
product
addit
p
aeruginosa
dna
led
increas
secret
unstimul
pg
protein
vs
dna
stimul
pg
protein
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
pretreat
azt
stimul
cell
reduc
secret
azt
azt
fig
assay
concentr
azt
medium
critic
obtain
effect
although
longer
preincub
time
eg
h
azt
vs
h
azt
need
lower
concentr
import
note
behavior
support
azt
action
weak
base
accumul
acidifi
intracellular
organel
act
sink
trap
azt
upon
proton
addit
effect
azt
basal
rant
level
measur
azt
reduc
rant
secret
fig
genet
polymorph
associ
elev
profibrot
mediat
tgfb
key
diseas
modifi
cf
elev
tgfb
increas
diseas
sever
report
gener
cf
respiratori
epitheli
cell
increas
compar
normal
cell
treatment
weak
base
cq
correct
releas
azt
test
reduc
fig
report
elev
cf
cell
caus
increas
furin
activ
intracellular
organel
cf
respiratori
epitheli
cell
henc
test
whether
azt
affect
furin
inbal
cf
cell
incub
azt
product
activ
furin
normal
cf
cell
par
cq
treatment
level
cftrcorrect
cell
fig
result
indic
correct
organellar
ph
azt
normal
excess
process
activ
furin
cf
cell
summari
azt
benefit
cf
explain
direct
antibiot
activ
due
physicalchem
action
weak
base
normal
organellar
function
cellautonom
respons
cf
respiratori
epitheli
cell
select
properti
altern
drug
azt
cpx
shown
tabl
togeth
cq
hcq
hydrophob
weak
base
drug
amin
pka
accord
hypothes
common
mechan
amount
base
absorb
per
mg
compound
also
calcul
combin
typic
dosag
rang
schedul
show
overal
like
amount
base
intracellular
acid
neutral
similar
amount
hcq
azt
cpx
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
conclus
relationship
demonstr
studi
indic
set
fdaapprov
drug
cq
azt
cpx
known
safeti
profil
act
control
ph
intracellular
organel
respiratori
epitheli
cell
highli
relev
target
furthermor
previou
studi
phosphodiesteras
inhibitior
show
similar
effect
may
also
test
alter
ph
organel
secretori
pathway
especi
tgn
may
alter
glycosyl
receptor
bind
spike
protein
glycosyl
protein
biogenesi
assembl
importantli
coronaviru
protein
govern
viral
bud
ertogolgi
intermedi
compart
penetr
deeper
golgi
apparatu
among
pathogen
cov
least
mer
cov
protein
possess
tgn
local
signal
effect
chloroquin
observ
virus
includ
hiv
glycosyl
defect
loss
infect
well
hsv
arrest
noninfecti
parti
tgn
studi
show
cf
respiratori
epitheli
cell
normal
base
neutral
preexist
patholog
hyperacidifi
compart
due
underli
cf
diseas
result
normal
glycosyl
cf
respiratori
epitheli
cell
postul
acidotrop
neutral
effect
azt
cpx
cq
normal
cell
would
result
vectori
similar
ph
shift
away
optim
function
enzym
within
secretori
pathway
would
also
alter
glycosyl
alter
ph
organel
endosom
pathway
may
effect
host
proteas
act
upon
spike
protein
execut
cleavag
necessari
viru
entri
inhibit
viral
entri
recent
cellular
system
best
achiev
combin
camostat
mesyl
inhibitor
proteas
plu
inhibitor
lysosom
cathepsin
note
unlik
sarscov
possess
novel
furin
cleavag
site
within
spike
protein
studi
show
azt
reduc
furin
activ
abundantli
present
respiratori
epitheli
cell
multipl
proteas
propos
cleav
spike
includ
also
act
sarscov
furin
lysosom
hydrolas
warrant
consider
gener
approach
inhibit
alter
ph
rather
focus
sole
specif
host
proteas
propos
drug
studi
cq
azt
cpx
may
modul
aspect
hostpathogen
interact
viru
infecti
cycl
immedi
compassion
use
clinic
control
clinic
trial
valid
effect
cpx
patient
would
enabl
util
drug
allevi
like
shortag
hcq
azt
cpx
part
us
health
human
servic
strateg
nation
stockpil
mobil
region
nation
emerg
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
method
cell
tissu
cultur
chemic
bronchial
epitheli
cell
line
deriv
cf
patient
cftr
mutant
genotyp
deriv
correct
chlorid
conduct
stabl
transfect
function
cftr
cell
maintain
media
biosourc
int
md
cf
cell
line
normal
human
bronchial
epitheli
gruenert
maintain
complet
memmedia
gibcobrl
life
technolog
md
normal
human
tracheal
cell
line
transfect
pcepr
pcep
p
davi
maintain
complet
dmem
gibcobrl
life
technolog
md
primari
bronchial
epitheli
cell
clonet
nhbe
p
karp
cf
lung
transplant
maintain
supplement
bemb
lonza
md
azt
fluke
switzerland
cpxhcl
sigma
st
loui
mo
transfect
microscopi
cellubrevin
fusion
ph
sensit
gfp
j
rothman
cell
transect
dna
use
effecten
siegen
ca
h
prior
measur
ph
co
focal
fluoresc
microscopi
fix
sampl
carri
zeu
meta
microscop
ratiometr
ph
determin
ratio
emiss
nm
upon
excit
nm
vs
nm
obtain
describ
previous
ph
standard
curv
gener
collaps
phgradient
incub
cell
monensin
nigericin
min
c
buffer
ph
ph
ratio
record
intern
standard
fluoresc
imag
taken
upon
excit
nm
consecut
exposur
three
region
interest
select
standard
curv
plot
averag
ratio
valu
given
buffer
ph
cell
incub
azt
h
hr
prior
determin
ph
ratio
sampl
read
standard
curv
convert
ph
unit
measur
cf
normal
cell
grown
post
confluenc
incub
h
azt
cell
fix
stain
fluoresc
label
cholera
toxin
b
h
room
temperatur
rel
fluoresc
calcul
actual
grey
level
random
field
independ
experi
postconflu
cell
treat
azt
incub
p
aeruginosa
multipl
infect
mem
media
without
serum
antibiot
supplement
sampl
wash
time
pb
lyse
cell
associ
bacteria
plate
p
aeruginosa
isol
agar
coloni
count
treatment
pseudomona
proinflammatori
lipopeptid
lipotoxin
lepta
activ
luciferas
assay
rant
analysi
carri
previous
describ
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
tgfb
product
furin
activ
analysi
level
determin
use
pail
assay
describ
previous
furin
enzym
activ
assay
presenc
triton
permeabil
agent
use
bocrvrramc
furin
substrat
fluoresc
measur
nm
excit
nm
emiss
wavelength
inhibitori
concentr
decrvkrcmk
calbiochem
exoamedi
cell
death
assess
employ
subsequ
experi
statist
unless
otherwis
specifi
statist
analys
carri
use
fisher
protect
lsd
post
hoc
test
anova
superanova
abacu
concept
thank
p
karp
j
zabner
primari
bronchial
epitheli
cell
cf
patient
lung
p
davi
p
zeitlin
cell
line
work
support
nih
grant
ai
ai
cystic
fibrosi
foundat
cff
grant
jfp
cff
postdoctor
fellow
vd
support
part
nih
grant
center
grant
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
e
top
row
untreat
primari
bronchial
cf
cell
bottom
row
primari
bronchial
cf
cell
treat
azt
color
lookup
tabl
r
ratio
emiss
intens
nm
upon
illumin
nm
c
tgn
ph
cf
cell
without
treatment
azt
cftrcorrect
cell
correct
tgn
ph
primari
cf
respiratori
epitheli
cell
azt
e
ratiometr
fluoresc
imag
cellubrevingfp
phluorin
primari
cf
respiratori
epitheli
cell
lung
transplant
f
correct
azt
cellubrein
endosom
ph
cf
cell
g
correct
azt
ph
cellubrevin
endosom
primari
cf
respiratori
epitheli
cell
lung
transplant
p
anova
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
ciprofolxacin
elev
tgn
ph
pcepr
cell
phenotyp
cf
cell
pcepr
transfect
phlourin
transfect
cell
treat
cpx
h
ph
determin
ratiometr
studi
azt
pcep
normal
cell
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
monolay
pretreat
treat
azt
drug
absent
adhes
assay
azt
reduc
activ
luciferas
report
cf
cell
respons
p
aeruginosa
ligand
deriv
lipoprotein
lpta
e
f
azt
reduc
basal
secret
induc
treatment
p
aeruginosa
dna
g
azt
reduc
basal
rant
product
cf
cell
p
anova
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
azt
reduc
product
furin
activ
cf
respiratori
epitheli
cell
azt
effect
secret
cf
cell
b
furin
level
correct
full
medium
azt
mm
chloroquin
cq
furin
inhibitor
cmk
use
measur
maximum
furin
inhibit
p
p
anova
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
